Optiscan has been featured in Dr. Boreham’s Crucible on The Australian, discussing the company’s advancements with AI integration and their pursuit of FDA clearance.

The article explores how these strategic focuses could elevate Optiscan's platform, particularly in enhancing real-time digital pathology and precision surgery. The combination of cutting-edge AI technology and regulatory approval holds potential for accelerating Optiscan's growth and transforming cancer diagnostics.

Read the full article here.